Tislelizumab & Tremelimumab Among Latest Filings In EU
The sponsors of two monoclonal antibody products, tislelizumab and tremelimumab, are each seeking marketing approval for more than one indication.
You may also be interested in...
Tislelizumab, Novartis/BeiGene’s drug for treating esophageal and non-small cell lung cancer, is among the latest new medicines that have been submitted for review for potential pan-EU approval.
Marinus’s ganaxolone has lost its accelerated assessment status mid-review at the European Medicines Agency while Roche’s glofitamab will be fast-tracked once a filing has been made.
Sanofi/GSK's vaccine is under review in the EU and the UK government has awarded a grant to a company to allow it to increase its production of a key component of mRNA vaccines. Also, EU member states have proposed ways of improving the supply and donation of COVID-19 vaccines, including for those fleeing the conflict in Ukraine. Germany’s InflaRx has reported “encouraging” results with its anti-inflammatory drug vilobelimab in seriously ill patients.